Trametinib represents potential new standard-of-care in ovarian cancer
A study led by researchers at the University of Texas MD Anderson Cancer Center reported in The Lancet that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian carcinoma.
Trametinib is market by Swiss pharma giant Novartis (NOVN: VX) under the trade name Mekinist and is used in combination with Tafinlar (dabrafenib), with the combo product generating 2021 sales of $1.7 billion for the company.
The international, multicenter Phase II/III trial led by Dr David Gershenson, professor of gynecologic oncology and reproductive medicine is the first positive randomized clinical trial of any therapy to demonstrate significantly increased progression-free survival (PFS) and objective response rate (ORR) in low-grade serous carcinoma, a rare and understudied form of ovarian cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze